| Detected | Trial | Change |
|---|---|---|
| 2026-08-12 | NCT07188844 An Open-Label Extension Study of Batoclimab in Adult Participants With Chronic… |
critical overall status: Enrolling by Invitation → Terminated |
| 2026-08-12 | NCT07188844 An Open-Label Extension Study of Batoclimab in Adult Participants With Chronic… |
critical Trial terminated: Sponsor Decision |
| 2026-08-12 | NCT07188844 An Open-Label Extension Study of Batoclimab in Adult Participants With Chronic… |
Enrollment reduced: 108 -> 26 participants |
| 2026-08-12 | NCT07188844 An Open-Label Extension Study of Batoclimab in Adult Participants With Chronic… |
date change Primary completion moved earlier: 2028-11 -> 2026-07-16 |
| 2026-08-12 | NCT07188844 An Open-Label Extension Study of Batoclimab in Adult Participants With Chronic… |
date change Completion moved earlier: 2028-11 -> 2026-07-16 |
| 2026-08-12 | NCT05581199 To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP |
critical Trial terminated |
| 2026-08-12 | NCT05581199 To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP |
critical Trial terminated: Sponsor Decision |
| 2026-08-12 | NCT05581199 To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP |
Enrollment reduced: 277 -> 94 participants |
| 2026-08-12 | NCT05581199 To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP |
Trial sites reduced: 116 -> 98 locations |
| 2026-08-12 | NCT05581199 To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP |
date change Primary completion pushed: 2026-01 -> 2026-07-20 |
| 2026-08-12 | NCT05581199 To Assess Efficacy and Safety of Batoclimab in Adult Participants With Active CIDP |
date change Completion moved earlier: 2027-01 -> 2026-07-20 |
| 2026-07-31 | NCT07032662 Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy… |
Trial sites expanded: 138 -> 141 locations |
| 2026-07-31 | NCT07039916 Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe… |
Trial sites expanded: 84 -> 88 locations |
| 2026-07-28 | NCT07286006 A Long-Term Extension Study of IMVT-1402 in Adult Participants With Graves' Disease (GD) |
Trial sites expanded: 93 -> 105 locations |
| 2026-07-28 | NCT07018323 A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for… |
Trial sites expanded: 154 -> 158 locations |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT07039916 | Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe… | Generalized Myasthenia Gravis | Recruiting |
| NCT05403541 | Phase 3 Study to Assess the Efficacy and Safety of Batoclimab as Induction and… | Generalized Myasthenia Gravis | Active, Not Recruiting |
| Phase 2 | |||
| NCT07032662 | Imeroprubart in Adult Participants With Chronic Inflammatory Demyelinating Polyneuropathy… | Chronic Inflammatory Demyelinating Polyneuropathy | Recruiting |
| NCT06727604 | A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for… | Graves' Disease | Recruiting |
| NCT06979531 | Efficacy and Safety of IMVT-1402 in Adult Participants With Primary Sjogren's Disease… | Primary Sjögren's Syndrome | Recruiting |
| NCT07018323 | A Study to Assess the Efficacy, Safety, and Tolerability of IMVT-1402 as Treatment for… | Graves' Disease | Recruiting |
| NCT06754462 | A Study to Evaluate the Efficacy, Safety, and Tolerability of IMVT-1402 in Adult… | Rheumatoid Arthritis | Active, Not Recruiting |
| NCT06980805 | A Study to Assess the Safety, Tolerability, and Efficacy of IMVT-1402 in Participants… | Subacute Cutaneous Lupus Erythematosus | Active, Not Recruiting |
| NCT07286006 | A Long-Term Extension Study of IMVT-1402 in Adult Participants With Graves' Disease (GD) | Graves' Disease | Enrolling by Invitation |